ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2275

Effect of Race and Lupus Nephritis on Pregnancy Outcomes in Systemic Lupus Erythematosus: An Individual Participant Meta-analysis

Ravyn Njagu1, Amanda Eudy 2, Stephen Balevic 3, Michelle Petri 4, Dafna Gladman 5, Murray Urowitz 6 and Megan Clowse 2, 1Duke University, Durham, NC, 2Duke University, Durham, 3Duke University, Hillsborough, NC, 4Johns Hopkins University School of Medicine, Baltimore, MD, 5Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, 6University Health Network, University of Toronto, Toronto, ON, Canada

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: health disparities, Lupus nephritis, pregnancy and meta-analysis, SLE

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Reproductive Issues In Rheumatic Disorders Poster

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Individual cohort studies have found that Black and Hispanic women have worse pregnancy outcomes compared to their white counterparts. Additionally, this population of women has a higher prevalence of lupus nephritis. Therefore, this individual participant meta-analysis pooled data from multiple lupus pregnancy cohorts to assess the effect of maternal race and nephritis on pregnancy outcomes.

Methods: PubMed, Embase, and the Cochrane Database of Systematic Reviews were searched for prospective cohorts of pregnancies among women with lupus. Data from each cohort was collected and analyzed individually. Race was classified as white or non-white. Outcomes of interest included fetal loss, preterm birth (< 37 weeks gestation), preeclampsia, and high disease activity (PGA ever >1 or SLEDAI ever >4 during pregnancy). Pooled ORs were calculated in Review Manager. The analysis included one pregnancy per patient in women with a first trimester visit.

Results: The analysis included 312 pregnancies across three cohorts in the United States and Canada, of which 46% were to non-white mothers and 22% were to women with history of nephritis. Overall, there was an increased risk of fetal loss among non-white patients compared to white patients (OR: 1.96; 95% CI: 1.02,3.77). History of nephritis did not have an association with fetal loss. In patients with no nephritis history, non-white women had a higher rate of fetal loss (OR: 2.16; 95% CI: 1.03,4.52). There was no significant effect of race on preterm birth overall, nor when stratified by history of nephritis . Overall, there was no significant effect of race on preeclampsia. Among white women, a history of nephritis increased the risk of preeclampsia (OR: 3.57; 95% CI: 0.92, 13.92). Overall, non-white patients were at increased risk of high disease activity during pregnancy (OR: 1.74; 95% CI: 0.99, 3.05). Among non-white women, history of nephritis increased the risk of high disease activity during pregnancy (OR: 3.22; 95% CI: 1.40-7.43).

Conclusion: Race is not the only factor driving health disparities in pregnancy outcomes among women with lupus. Additionally, these differences are not entirely explained by the increased prevalence of nephritis in non-white women. When managing lupus in pregnancy, race and history of nephritis are important considerations. However, additional studies are needed to further elucidate why non-white women continue to have disproportionately worse outcomes.


Table 1

Table 1. Summary of pooled odds ratios for the association of maternal race with pregnancy outcomes


Table 2

Table 2. Summary of pooled odds ratios for the association of maternal with pregnancy outcomes


Disclosure: R. Njagu, None; A. Eudy, GSK, 2; S. Balevic, UCB, 5, Rheumatology Research Foundation, 2, Thrasher Research Foundation, 2, NIH, 2; M. Petri, Eli Lilly and Company, 5, Exagen, 2, 5; D. Gladman, AbbVie, 2, 5, Amgen, 2, 5, BMS, 5, Celgene, 2, 5, Eli Lilly, 2, 5, Galapagos, 5, Galapagos NV, 5, Gilead, 5, GSI, 5, Janssen, 5, Janssen Research & Development, LLC, 2, Novartis, 2, 5, Pfizer, 2, 5, UCB, 2, 5; M. Urowitz, Janssen Research & Development, LLC, 2, UCB Pharma, 9; M. Clowse, GSK, 2, UCB, 5.

To cite this abstract in AMA style:

Njagu R, Eudy A, Balevic S, Petri M, Gladman D, Urowitz M, Clowse M. Effect of Race and Lupus Nephritis on Pregnancy Outcomes in Systemic Lupus Erythematosus: An Individual Participant Meta-analysis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/effect-of-race-and-lupus-nephritis-on-pregnancy-outcomes-in-systemic-lupus-erythematosus-an-individual-participant-meta-analysis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-race-and-lupus-nephritis-on-pregnancy-outcomes-in-systemic-lupus-erythematosus-an-individual-participant-meta-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology